Table 3. Baseline characteristics of the CHB patients receiving a liver biopsy.

Cases	Gender	Age	G (Inflammation)	S (Fibrosis)	ALT (U/L)	AST (U/L)	HBeAg (+/−)	HBVDNA (+/−)	Immune phase
1	Female	29	0	0	16	26	-	+	IT
2	Female	24	0	0	123	72	+	+	IC
3	Male	40	0	1	49	47	+	+	IC
4	Male	38	0	1	116	41	+	+	IC
5	Female	56	0	1	23	24	-	-	LR
6	Female	27	1	0	10	17	-	+	LR
7	Male	29	1	0	67	45	+	+	IC
8	Male	46	1	0	54	47	-	+	ENH
9	Male	38	1	1	109	87	+	+	IC
10	Female	35	1	1	97	48	-	+	ENH
11	Female	31	1	0	11	21	+	+	IT
12	Male	29	1	1	56	35	+	+	IC
13	Male	40	0	2	21	25	+	+	IT
14	Male	47	1	2	102	77	+	-	ENH
15	Female	19	2	0	23	42	+	+	IT
16	Male	40	2	1	18	18	+	-	LR
17	Male	31	2	2	155	74	+	+	IC
18	Male	36	2	1	262	94	+	+	IC
19	Male	23	3	2	225	110	+	+	IC
20	Female	41	3	3	89	62	+	+	IC
21	Male	20	2	3	107	61	-	-	ENH
22	Female	47	3	4	310	105	+	+	IC
23	Male	31	4	3	166	121	+	+	IC
24	Female	47	2	4	132	105	+	+	IC
25	Male	39	4	3	176	102	+	+	IC
Control1	Male	39	0	0	22	35	-	-	NA
Control2	Male	34	0	0	31	28	-	-	NA
Control3	Male	41	0	0	18	29	-	-	NA
Control4	Female	28	0	0	27	21	-	-	NA

IT, immune tolerance phase; IC, immune clearance phase; LR, low-replicative phase; ENH, HBeAg-negative hepatitis phase; HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase; AST, aspartate aminotransferase;